OncoMatch/Clinical Trials/NCT04516447
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Is NCT04516447 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for solid tumor.
Treatment: Azenosertib · Carboplatin · Pegylated liposomal doxorubicin · Paclitaxel · Gemcitabine · Bevacizumab — This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Ovarian Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
Grade: high-grade
FIGO Stage III/IV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma
Demographics
Prior therapy
Must have received: platinum-based chemotherapy (cisplatin, carboplatin) — advanced or metastatic
At least one regimen must have contained cisplatin or carboplatin
Must have received: platinum-based doublet chemotherapy — 1L or 2L
Subjects must have received 6 cycles of platinum-based doublet chemotherapy in the 1L or 2L setting as their most recent therapy
Must have received: platinum-based chemotherapy — 2L
Subjects must have at least 4 cycles of platinum-based chemotherapy in 2L and have Complete Response, Partial Response, or Stable Disease
Must have received: PARP inhibitor — 1L maintenance
Subjects must have progressed while on a PARP inhibitor for 1L maintenance
Lab requirements
Blood counts
Kidney function
Liver function
Adequate hematologic, and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 0264 · Aurora, Colorado
- Site 0104 · Boston, Massachusetts
- Site 0111 · St Louis, Missouri
- Site 0173 · New York, New York
- Site 0259 · Durham, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04516447 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and platinum-based doublet chemotherapy.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages